CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

(MENAFN- ForPressRelease) Dubai, UAE, November 2025: Pedal Mobility, a leading innovator in driver training technology, today announced the launch of its upgraded Driver Training Software, a ...

BMW’s M Division is responsible for some of the most legendary enthusiast cars ever put to pavement. And while the titular M1 was the motorsport division’s first serialized road car, it was not the ...

CSL will invest $2.3 billion to expand its North American manufacturing facilities over the next five years, joining other global pharmaceutical companies seeking exemptions from US President Donald ...

While it's an expensive add-on, Trak Racer's haptic kit delivers excellent immersion and is well worth considering for your ...

A leading investment expert delivers his verdict on the outlook for CSL's beaten-down shares. CSL shares have tumbled 35% in 2025, partly attributed to an underwhelming FY 2025 results release and ...